IL252258D0 - Anti-mutated kras t cell receptors - Google Patents

Anti-mutated kras t cell receptors

Info

Publication number
IL252258D0
IL252258D0 IL252258A IL25225817A IL252258D0 IL 252258 D0 IL252258 D0 IL 252258D0 IL 252258 A IL252258 A IL 252258A IL 25225817 A IL25225817 A IL 25225817A IL 252258 D0 IL252258 D0 IL 252258D0
Authority
IL
Israel
Prior art keywords
cell receptors
mutated kras
kras
mutated
receptors
Prior art date
Application number
IL252258A
Other languages
Hebrew (he)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462084654P priority Critical
Priority to US201562171321P priority
Priority to PCT/US2015/062269 priority patent/WO2016085904A1/en
Application filed by Us Health filed Critical Us Health
Publication of IL252258D0 publication Critical patent/IL252258D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras, Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
IL252258A 2014-11-26 2017-05-14 Anti-mutated kras t cell receptors IL252258D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201462084654P true 2014-11-26 2014-11-26
US201562171321P true 2015-06-05 2015-06-05
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Publications (1)

Publication Number Publication Date
IL252258D0 true IL252258D0 (en) 2017-07-31

Family

ID=54838442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252258A IL252258D0 (en) 2014-11-26 2017-05-14 Anti-mutated kras t cell receptors

Country Status (16)

Country Link
US (1) US20170304421A1 (en)
EP (2) EP3666288A1 (en)
JP (1) JP2017536825A (en)
KR (1) KR20170099905A (en)
CN (1) CN107223134A (en)
AU (2) AU2015353720B2 (en)
CA (1) CA2968399A1 (en)
ES (1) ES2784261T3 (en)
HK (1) HK1243642A1 (en)
IL (1) IL252258D0 (en)
MX (1) MX2017006865A (en)
PL (1) PL3223850T3 (en)
PT (1) PT3223850T (en)
SG (2) SG10201913978RA (en)
SI (1) SI3223850T1 (en)
WO (1) WO2016085904A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913868XA (en) 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
KR20200051804A (en) * 2017-09-20 2020-05-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 HLA class II-restricted T cell receptor for mutated RAS
WO2019112941A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (en) * 1998-05-08 2003-08-04 Gemvax As Peptides derived from the reading frame shift mutations in TBF <beta> II or BAX gene, and pharmaceutical compositions containing these nucleic acid sequences encoding such peptides, plasmids and virusvektoreromfattende slikenukleinsy
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2008089053A2 (en) * 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CA2774349C (en) * 2009-09-17 2019-03-19 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN108395479A (en) * 2017-02-06 2018-08-14 高军 A kind of T cell receptor in relation to KRAS gene mutation

Also Published As

Publication number Publication date
SG10201913978RA (en) 2020-03-30
AU2015353720A1 (en) 2017-06-08
EP3666288A1 (en) 2020-06-17
PL3223850T3 (en) 2020-08-24
SI3223850T1 (en) 2020-09-30
MX2017006865A (en) 2018-01-11
EP3223850A1 (en) 2017-10-04
SG11201704155UA (en) 2017-06-29
ES2784261T3 (en) 2020-09-23
JP2017536825A (en) 2017-12-14
AU2020203465A1 (en) 2020-06-18
CA2968399A1 (en) 2016-06-02
AU2015353720B2 (en) 2020-02-27
US20170304421A1 (en) 2017-10-26
WO2016085904A1 (en) 2016-06-02
CN107223134A (en) 2017-09-29
HK1243642A1 (en) 2018-07-20
PT3223850T (en) 2020-04-13
KR20170099905A (en) 2017-09-01
EP3223850B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
HRP20191704T1 (en) Multispecific antibodies
GB2531928B (en) Image-stitching for dimensioning
IL250583D0 (en) Anti-tigit antibodies
HK1217861A1 (en) Wifi-coordinated laa-lte
GB201817189D0 (en) Image-stitching for dimensioning
ZA201608378B (en) Improved t cell compositions
PL3227332T3 (en) Multispecific antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
IL274903D0 (en) Cell
GB201410907D0 (en) No details
SG11201703346PA (en) Anti-tim-3 antibodies
HK1246825A1 (en) Cell
GB201414823D0 (en) Multispecific antibodies
PL3101756T3 (en) Charging system
GB2528557B (en) Soundbar
GB201516146D0 (en) None
AU361515S (en) Dishrack
PL3097397T3 (en) Schienenmesssystem
GB201404893D0 (en) Selfie - Stick
GB201516266D0 (en) None
GB201407805D0 (en) Battery condition determination
PL3509156T3 (en) Electrolyte solution
PL3200257T3 (en) Separator for battery
GB201418216D0 (en) No details
GB2529896B (en) Multirotor